Flora Peyvandi, MD, PhD

Full Professor
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Università degli Studi di Milano, Department of Pathophysiology and Transplantation
Milan, Lombardia, Italy

Presentation(s):

• EC 01.2 - Welcome message

  Saturday, June 22, 2024
  08:05 – 08:15 ICT

• GG 01.1 - Welcome

  Saturday, June 22, 2024
  09:30 – 09:32 ICT

• GG 01.7 - Global recommendations for TTP Q&A

  Saturday, June 22, 2024
  10:25 – 10:30 ICT

• LB 01.6 - Late-Breakthrough Session

  Sunday, June 23, 2024
  09:30 – 10:45 ICT

• OC 14.1 - Perioperative management with efanesoctocog alfa in adults, adolescents, and children with severe hemophilia A in the phase 3 XTEND clinical program

  Sunday, June 23, 2024
  09:30 – 09:45 ICT

• PB0347 - Clinical and Laboratory Characteristics of Patients with Acquired von Willebrand Syndrome

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0243 - Detection of an anti-drug antibody against emicizumab in clinical practice: experience from one center in France

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0300 - Estimating the population-based prevalence of congenital TTP using 807,162 exome and genome sequencing from gnomAD

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0197 - Gynecological and obstetrical complications in women with congenital fibrinogen deficiencies

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0220 - miR-128 in severe hemophilia-A patients with and without inhibitor

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0272 - Novel insight into the genetic background of Low VWF using whole exome sequencing

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0211 - Prevalence of advanced fibrosis/cirrhosis in people with hemophilia: results from a non-invasive screening based on international hepatological recommendations.

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0182 - Results from the Hypoplasminogenemia International retroSpecTive and prOspective cohoRt studY (HISTORY) on plasminogen deficiency

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0223 - Standardized and Centralized Global Database on Gene Therapy Data – The World Federation of Hemophilia Gene Therapy Registry

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0240 - The role of anti-emicizumab antibodies and their clinical relevance

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• OC 26.2 - Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: update of an Italian multicenter study

  Sunday, June 23, 2024
  15:00 – 15:15 ICT

• OC 26.5 - Predisposing conditions and drugs to caplacizumab-related bleeding episodes in patients with acute immune-mediated TTP: real-world data from the Milan Center

  Sunday, June 23, 2024
  15:45 – 16:00 ICT

• OC 30.2 - Efficacy and safety of valoctocogene roxaparvovec 4 years after gene transfer in GENEr8-1

  Monday, June 24, 2024
  09:45 – 10:00 ICT

• PB0500 - Communicating gene editing in hemophilia: development of a universal lexicon

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0537 - Development of novel gene editing lexicon for hemophilia: methodology and results

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0906 - Risk factors for venous thromboembolism after surgery for lung transplantation

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• OC 40.3 - Hepatobiliary events in the fitusiran clinical development program with the revised AT-based dose regimen

  Monday, June 24, 2024
  15:15 – 15:30 ICT

• SSC 018.1 - Session Welcome (Part 1: How to manage a patient for gene therapy)

  Monday, June 24, 2024
  16:30 – 16:35 ICT

• PB1326 - Clinical severity of the first episode and risk of recurrent neurological symptoms in relapses among patients with immune-mediated thrombotic thrombocytopenic purpura

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1085 - The histopathological landscape of synovitis in hemophilic arthropathy

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• OC 62.3 - The risk of cerebral vein thrombosis associated with different types of oral contraceptives: a case-control study

  Tuesday, June 25, 2024
  15:15 – 15:30 ICT

• OC 63.1 - Type 2M/2A von Willebrand disease: A shared phenotype between type 2M and 2A

  Tuesday, June 25, 2024
  14:45 – 15:00 ICT

• OC 71.5 - Joint health and quality of life scores from baseline to one year after switching to emicizumab

  Wednesday, June 26, 2024
  11:15 – 11:30 ICT

• OC 73.1 - The genetic spectrum of patients with rare bleeding disorders

  Wednesday, June 26, 2024
  10:15 – 10:30 ICT